Skip to main content
Press Release

Fieldfisher advises Ultromics on $33 million Series B funding

16/08/2021

Locations

United Kingdom

The firm's Life Sciences team advised leader in AI enabled cardiovascular imaging solutions, Ultromics, on its equity financing round to help transform cardiac disease treatment.

International law firm Fieldfisher has advised UK headquartered medtech company Ultromics on its $33 million Series B funding round led by the Blue Venture Fund with participation from Optum Ventures, GV, and existing investor Oxford Sciences Innovation.
 
Founded in 2017 by Dr Ross Upton and Professor Paul Leeson, as a spin out from the University of Oxford and built-in partnership with the U.K.'s National Health Service (NHS). Ultromics’ EchoGo Core and EchoGo Pro platforms quickly deliver highly accurate assessments of heart function that support the diagnosis of coronary artery disease, heart failure and amyloidosis.   Ultromics provides autonomous echocardiography analysis through innovative AI solutions, giving accurate decisions when diagnosing cardiovascular disease, the leading cause of mortality in the world.
 
Echocardiography is the most cost efficient and safest way of imaging of the heart and Ultromics' revolutionary AI technology improves the accuracy allowing it to be equally effective to alternatives that are more expensive.
 
Ultromics plans to use the Series B funding to accelerate validating and scaling their technology with the support of their investors.
 
 Dr. Janita Good, co-head of Life Sciences at Fieldfisher commented:
 
We are delighted to have worked with Ultromics on this crucial fundraising. Ultromics' ground-breaking technology has the power to revolutionise the way healthcare providers diagnose and then treat cardiovascular disease.
 
This fundraising is another example of the appetite for the much-needed innovation that comes from the UK life sciences sector.
 
 Fieldfisher's life sciences sector group has a strong reputation for working with the world's most innovative life sciences companies bringing about real change in healthcare.
 
We wish Ultromics every success in the future and look forward to seeing how they continue to grow internationally.



 About Fieldfisher
 
Fieldfisher is an International law firm with market-leading practices in many of the world's most dynamic sectors. We are an exciting, forward-thinking organisation with a particular focus on life sciences, technology, financial services, energy & natural resources.
 
Fieldfisher has 25 offices across 11 countries, with dedicated life sciences expertise in each country.
 
We operate across our offices in Amsterdam, Barcelona, Beijing, Belfast, Birmingham, Bologna, Brussels, Dublin, Düsseldorf, Frankfurt, Guangzhou, Hamburg, London, Luxembourg, Madrid, Manchester, Milan, Munich, Paris, Rome, Shanghai, Turin, Venice and Silicon Valley.

Sign up to our email digest

Click to subscribe or manage your email preferences.

SUBSCRIBE

Areas of Expertise

Corporate

Related Work Areas

Life Sciences